Bendamustine
| Generic name | Bendamustine |
| Pronunciation | ben-da-MUS-teen |
| Brand name(s), other common name(s) | Treanda® |
| Drug type | Alkylating agent |
| How the drug is given | Intravenously (IV) |
Bendamustine is FDA approved to treat people who have chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma (NHL) that has progressed during or within
6 months of treatment with rituximab or a rituximab-containing regimen.
Side effects needing medical attention:
Infection, injection reaction, skin reactions.
For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.
